Outsourced Pharma Capacity Update Videos - Large Molecule

  1. Resilience Capacity Update July 2025: Large Molecule Drug Substance 7/28/2025

    Hear from Evan Pasenello, Head of Commercial Services, about how Resilience can support large molecule programs from early phase through clinical and commercial manufacturing.

  2. Novartis Contract Manufacturing Capacity Update July 2025: Large Molecule Drug Substance 7/28/2025

    Review biologics CDMO solutions and capacity offered by Novartis Contract Manufacturing. We discuss our capabilities in mammalian cell culture manufacturing and microbial fermentation.

  3. FUJIFILM Biotechnologies Capacity Update July 2025: Large Molecule Drug Substance 7/28/2025

    Review the strategic application of extensive expertise in microbial systems to meet the increasing demand for novel biologics. Cutting-edge capabilities ensure streamlined development and manufacturing processes.

  4. Cytovance Biologics Capacity Update July 2025: Large Molecule Drug Substance 7/28/2025

    Thomas Kohl, Director of Business Development, shares the company’s microbial and mammalian capabilities and their available capacity. Cytovance delivers ingenuity end-to-end to both large pharma and biotech clients alike.

  5. Aragen Capacity Update July 2025: Large Molecule Drug Substance 7/28/2025

    Aragen’s newly built cutting-edge biologics manufacturing facility launches with GMP capabilities from 50L to 2000L—scaling to 5000L soon—with a DP filling line and ADC conjugation suite set to redefine bioproduction in India.

  6. Northway Biotech Capacity Update April 2025: Large Molecule Development 4/22/2025

    Detra Glinatsis, Vice President of Business Development, presents the advanced capabilities, strategic growth, and expanding capacity of Northway Biotech, a global biologics CDMO.

  7. Abzena Capacity Update April 2025: Large Molecule Development 4/22/2025

    See first-hand how AbZelectPRO™, an evolved approach to cell line development, can simplify selection, enhance stability, and de-risk your program for faster regulatory approval.

  8. Curia Capacity Update April 2025: Large Molecule Development 4/22/2025

    Site head Bill Hermans showcases our facility's specialized capabilities in Hopkinton, Massachusetts, and shares how our team serves as a true scientific partner to clients.

  9. Cytovance Biologics Capacity Update April 2025: Large Molecule Development 4/22/2025

    Speed up your program with end-to-end microbial and mammalian biologics development and manufacturing expertise — spanning everything from biosimilars to vaccines.

  10. Novartis Capacity Update April 2025: Large Molecule Development 4/22/2025

    Experience a global network of expertise and proven manufacturing capabilities that can help accelerate your clinical and commercial drug substance programs.